Etrolizumab in UC: Etrolizumab/placebo for anti-TNF naive patients

Print

Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989
smikolainis@mtsinai.on.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectation: Open label for 10 weeks then responders will go into a blinded Maintenance phase, open label extension study possible at week 62 or after week 10 for nonresponders

Eligibility

  • Mayo score 6 -12 (bleeding subscore >1)
  • Naive to anti-TNF therapy
  • Inadequate response, loss of response to or intolerance to immunomodulators/steroids within past 5 years
  • Subcutaneous injection


Exclusions
: strictures, prior tx with anti-integrin agents (vedolizumab)

WE INVITE YOU TO PARTNER WITH US TODAY
Donate to the Zane Cohen Centre
Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex. Copyright © 1997 - 2017.
All Rights Reserved. A patient care, teaching and research centre affiliated with University of Toronto.
Powered by Joomla 1.7 Templates